2 results about "Iopromide" patented technology

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

This invention relates to a method for preparing iodine-based nanocontrast agents. Based on the specific and efficient esterification reaction between fluorinated phenylboronic acid groups and ortho-dihydroxy structures, an amphiphilic block polymer containing fluorinated phenylboronic acid groups is co-crosslinked with water-soluble nonionic polyhydroxy iodine-based contrast agents such as iohexol, iodofol, iodixanol, iopromide, iodomeprazole, iodiphenol, iodpentol, and iotram. No chemical modification of the iodine-based contrast agents is required. The water-soluble nonionic polyhydroxy iodine-based contrast agents can be easily and efficiently nano-sized through the phenylboronic acid esterification crosslinking reaction to obtain iodine-based nanocontrast agents. This invention has the advantages of a simple and controllable preparation process, mild reaction conditions, inexpensive and readily available raw materials, and no toxic byproducts. Furthermore, the prepared iodine-based nanocontrast agents exhibit good dispersion stability and excellent imaging contrast performance. When the concentration of the iodine-based nanocontrast agent reaches 120 mg / mL, the CT value reaches as high as 1150 HU.